个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

The first Chinese National Union of Real-world Gynaecological Oncology Research and Patient Management Platform: A retrospective study

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Zeng, Shaoqing[1,2] * ; Chi, Jianhua[1,2] ; Liu, Jiahao[1,2] ; Jiao, Xiaofei[1,2] ; Liu, Xingyu[1,2] ; Yu, Yang[1,2] ; Li, Ruyuan[1,2] ; Huo, Yabing[1,2] ; Ma, Guanchen[1,2] ; Zhao, Yingjun[1,2] ; Wang, Li[3,4] ; Zhou, Qi[5,6] ; Zou, Dongling[5,6] ; Cheng, Xiaodong[7] ; Li, Qingshui[8] ; Wang, Jing[9,10,11] ; Yao, Shuzhong[12] ; Zhao, Weidong[13,14] ; Xia, Bairong[13] ; Chen, Youguo[15] ; Fan, Jiangtao[16] ; Wang, Wei[17] ; Hong, Li[18] ; Guo, Ruixia[19] ; Liu, Ziling[20] ; Gao, Yunong[21] ; Li, Jundong[22,23] ; Zhang, Bei ; Yu, Jinjin ; Hu, Ting[1,2] ; Zhang, Wei[1,2] ; Shan, Wanying[1,2] ; Peng, Zikun[1,2] ; Li, Ming[1,2] ; Xie, Xing[1,7] ; Ma, Ding[1,2] ; Gao, Qinglei[1,2] ;
单位： [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Natl Clin Res Ctr Obstet & Gynecol, Canc Biol Res Ctr,Key Lab,Minist Educat,Tongji Hos, Wuhan, Peoples R China [2]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Dept Gynecol & Obstet,Wuhan 430030,Peoples R China [3]Zhengzhou Univ, Affiliated Canc Hosp, Dept Canc Biol Immunotherapy, Zhengzhou, Peoples R China [4]Henan Canc Hosp, Zhengzhou, Peoples R China [5]Chongqing Univ, Canc Hosp, Dept Gynecol Oncol, Chongqing, Peoples R China [6]Chongqing Univ Canc Hosp, Chongqing Key Lab Translat Res Canc Metastasis & I, Chongqing, Peoples R China [7]Zhejiang Univ, Womens Hosp, Sch Med, Dept Gynecol Oncol, Hangzhou, Peoples R China [8]Shandong Canc Hosp & Inst, Dept Gynecol Oncol, Jinan, Peoples R China [9]Cent South Univ, Xiangya Sch Med, Hunan Canc Hosp, Hunan Clin Res Ctr Gynecol Canc, Changsha, Peoples R China [10]Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Peoples R China [11]Cent South Univ, Hunan Canc Hosp, Xiangya Sch Med, Dept Gynecol Canc, Changsha, Peoples R China [12]Sun Yat Sen Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Guangzhou, Peoples R China [13]Anhui Prov Canc Hosp, Dept Gynecol & Oncol, Hefei, Peoples R China [14]Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Obstet & Gynecol, Div Life Sci & Med, Hefei, Peoples R China [15]Soochow Univ, Affiliated Hosp 1, Dept Gynecol & Obstet, Suzhou, Peoples R China [16]Guangxi Med Univ, Affiliated Hosp 1, Dept Gynecol, Nanning, Peoples R China [17]Guangzhou Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Guangzhou, Peoples R China [18]Wuhan Univ, Renmin Hosp, Dept Gynecol & Obstet, Wuhan, Peoples R China [19]Zhengzhou Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Zhengzhou, Peoples R China [20]First Hosp Jilin Univ, Dept Oncol, Jilin, Peoples R China [21]Peking Univ Canc Hosp & Inst, Dept Gynaecol Oncol, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China [22]Sun Yat sen Univ, Canc Ctr, Dept Gynecol Oncol, Guangzhou, Peoples R China [23]Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
出处：
DOI： 10.1111/1471-0528.17328
ISSN：

关键词： breast cancer gene testing gynaecologic oncology ovarian cancer real-world study treatment patterns

摘要：
ObjectiveTo produce high-quality, real-world evidence for oncologists by collating scattered gynaecologic oncology (GO) medical records in China. DesignRetrospective study. SettingThe National Union of Real-world Gynaecological Oncology Research and Patient Management Platform (NUWA platform). SamplePatient-centred data pool. MethodsThe NUWA platform integrated inpatient/outpatient clinical, gene and follow-up data. Data of 11 456 patients with ovarian cancer (OC) were collected and processed using 91 345 electronic medical records. Structured and unstructured data were de-identified and re-collated into a patient-centred data pool using a predefined GO data model by technology-aided abstraction. Main Outcome MeasuresRecent treatment pattern shifts towards precision medicine for OC in China. ResultsThirteen first-tier hospitals across China participated in the NUWA platform up to 7 December 2021. In total, 3504 (30.59%) patients were followed up by a stand-alone patient management centre. The percentage of patients undergoing breast cancer gene (BRCA) mutation tests increased by approximately six-fold between 2017 and 2018. A similar trend was observed in the administration rate of poly(ADP-ribose) polymerase inhibitors as first-line treatment and second-line treatment after September 2018, when olaparib was approved for clinical use in China. ConclusionThe NUWA platform has great potential to facilitate clinical studies and support drug development, regulatory reviews and healthcare decision-making.

基金：
Beijing Kanghua Foundation for the Development of Traditional Chinese and Western Medicine; National Key Technology Research and Development Programme of China; National Science Foundation of China [2022YFC2704200]; Major Project of the Chinese Society of Medical Education [81772787, 82072889]; Beijing Xisike Clinical Oncology Research Foundation [20A0769]; [Y-2019AZZD-0359]; [Y- 2019AZQN- 0385]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 1 区 医学
小类 | 1 区 妇产科学
最新[2025]版：
大类 | 2 区 医学
小类 | 1 区 妇产科学
JCR分区：
出版当年[2020]版：
Q1 OBSTETRICS & GYNECOLOGY
最新[2023]版：
Q1 OBSTETRICS & GYNECOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者：
第一作者单位： [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Natl Clin Res Ctr Obstet & Gynecol, Canc Biol Res Ctr,Key Lab,Minist Educat,Tongji Hos, Wuhan, Peoples R China [2]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Dept Gynecol & Obstet,Wuhan 430030,Peoples R China
通讯作者：
通讯机构： [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Natl Clin Res Ctr Obstet & Gynecol, Canc Biol Res Ctr,Key Lab,Minist Educat,Tongji Hos, Wuhan, Peoples R China [2]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Dept Gynecol & Obstet,Wuhan 430030,Peoples R China
推荐引用方式(GB/T 7714)：
Zeng Shaoqing,Chi Jianhua,Liu Jiahao,et al.The first Chinese National Union of Real-world Gynaecological Oncology Research and Patient Management Platform: A retrospective study[J].BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY.2022,129:60-69.doi:10.1111/1471-0528.17328.
APA：
Zeng, Shaoqing,Chi, Jianhua,Liu, Jiahao,Jiao, Xiaofei,Liu, Xingyu...&Gao, Qinglei.(2022).The first Chinese National Union of Real-world Gynaecological Oncology Research and Patient Management Platform: A retrospective study.BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY,129,
MLA：
Zeng, Shaoqing,et al."The first Chinese National Union of Real-world Gynaecological Oncology Research and Patient Management Platform: A retrospective study".BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY 129.(2022):60-69

相关文献

[1]Real-world treatment patterns and clinical outcomes in EGFR-mutant locally advanced lung adenocarcinoma: A multi-center cohort study [2]Does the primary treatment sequence affect post-relapse survival in recurrent epithelial ovarian cancer? A real-world multicentre retrospective study [3]Real-world surgical treatment patterns and clinical outcomes in patients with stages IA-IIIA non-small cell lung cancer: a retrospective multicentric observational study involving 11,958 patients [4]Treatment (tx) patterns in resectable stage IAeIIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study [5]Clinical Characters of the Diagnosis and Treatment of Gynecological Malignant Tumors in China : A Real World Study [6]Real-world Study Optimizing Nucleotide-analogues [7]Real-world treatment patterns and clinical outcomes in EGFR-mutant unresectable locally advanced NSCLC (LA-NSCLC): A retrospective multicenter study of 367 patients. [8]Real-world treatment patterns and clinical outcomes in EGFR-mutant unresectable locally advanced NSCLC (LA-NSCLC): A retrospective multicenter study of 367 patients [9]Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study [10]TAF Real World Study for Universal Effectiveness (TRUE)

资源点击量：426 今日访问量：0 总访问量：408 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）